Arovella Therapeutics Limited
Arovella Therapeutics Limited (ALA.AX) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Arovella Therapeutics Limited (ALA.AX), covering cash flow, earnings, and balance sheets.
Arovella Therapeutics Limited (ALA.AX) Income Statement & Financial Overview
View the income breakdown for Arovella Therapeutics Limited ALA.AX across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $4250.00 | $4250.00 | $8500.00 | $971811.00 |
| Cost of Revenue | $20162.00 | $0.00 | $1.47M | $0.00 |
| Gross Profit | -$15912.00 | $4250.00 | -$1.46M | $971811.00 |
| Gross Profit Ratio | -$3.74 | $1.00 | -$172.21 | $1.00 |
| R&D Expenses | $1.54M | $1.54M | $3.66M | $1.83M |
| SG&A Expenses | $480200.00 | $480200.00 | $835582.00 | $724722.00 |
| Operating Expenses | $2.02M | $2.02M | $4.49M | $2.98M |
| Total Costs & Expenses | $2.02M | $2.02M | $5.97M | $2.98M |
| Interest Income | $52532.00 | $0.00 | $86203.00 | $38786.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $20162.00 | $10081.00 | $22817.00 | $11409.00 |
| EBITDA | -$2.42M | -$2.42M | -$5.86M | -$2.000M |
| EBITDA Ratio | -$568.55 | -$568.55 | -$698.31 | -$2.06 |
| Operating Income | -$2.01M | -$2.01M | -$5.96M | -$2.01M |
| Operating Income Ratio | -$473.89 | -$473.89 | -$701.00 | -$2.07 |
| Other Income/Expenses (Net) | -$386082.00 | -$386082.00 | $77572.00 | $38786.00 |
| Income Before Tax | -$2.40M | -$2.40M | -$5.88M | -$1.97M |
| Income Before Tax Ratio | -$564.74 | -$564.74 | -$691.87 | -$2.03 |
| Income Tax Expense | $0.00 | -$412348.00 | -$1.94M | $0.00 |
| Net Income | -$2.40M | -$2.40M | -$3.95M | -$1.97M |
| Net Income Ratio | -$564.74 | -$564.74 | -$464.21 | -$2.03 |
| EPS | -$0.002 | -$0.002 | -$0.004 | -$0.002 |
| Diluted EPS | -$0.002 | -$0.002 | -$0.004 | -$0.002 |
| Weighted Avg Shares Outstanding | $982.45M | $982.45M | $900.51M | $896.77M |
| Weighted Avg Shares Outstanding (Diluted) | $982.33M | $982.33M | $900.51M | $900.51M |
The company's financials show resilient growth, with revenue advancing from $971811.00 in Q1 2024 to $4250.00 in Q4 2024. Gross profit remained healthy with margins at -374% in Q4 2024 compared to 100% in Q1 2024. Operating income hit -$2.01M last quarter, sustaining a consistent -47389% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$2.42M. Net income rose to -$2.40M, while earnings per share reached -$0.002. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan